Wall Street Zen Upgrades Outset Medical (NASDAQ:OM) to Hold

Outset Medical (NASDAQ:OM) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings upgraded Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. TD Cowen reiterated a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $10.00.

Outset Medical Price Performance

Shares of OM stock opened at $4.51 on Friday. Outset Medical has a 1 year low of $3.00 and a 1 year high of $16.16. The company has a current ratio of 5.19, a quick ratio of 4.11 and a debt-to-equity ratio of 1.03. The firm’s 50 day moving average is $4.58 and its 200-day moving average is $4.25. The firm has a market capitalization of $84.79 million, a price-to-earnings ratio of -1.10 and a beta of 1.96.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. The company had revenue of $31.64 million during the quarter, compared to analyst estimates of $28.97 million. Sell-side analysts forecast that Outset Medical will post -3.9 EPS for the current fiscal year.

Insider Transactions at Outset Medical

In other Outset Medical news, CFO Renee Gaeta sold 17,672 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $4.94, for a total value of $87,299.68. Following the transaction, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at approximately $561,939.82. This trade represents a 13.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new position in shares of Outset Medical in the 4th quarter worth $29,000. Legal & General Group Plc bought a new stake in Outset Medical in the second quarter valued at about $34,000. BNP Paribas Financial Markets lifted its stake in Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after buying an additional 2,034 shares during the period. Hsbc Holdings PLC bought a new position in Outset Medical during the fourth quarter worth about $46,000. Finally, HRT Financial LP bought a new position in Outset Medical during the fourth quarter worth about $58,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.